Hanne Ehrlinder
Overview
Explore the profile of Hanne Ehrlinder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
76
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papakonstantinou P, Rivera-Caravaca J, Chiarito M, Ehrlinder H, Iliakis P, Gasecka A, et al.
Trends Cardiovasc Med
. 2025 Jan;
PMID: 39862940
Atrial fibrillation (AF) and atrial myopathy are recognized contributors to cardiovascular morbidity, particularly ischemic stroke. AF poses an elevated risk of thrombogenesis due to irregular heart rhythm leading to blood...
2.
Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction
Karaban K, Slupik D, Reda A, Gajewska M, Rolek B, Borovac J, et al.
Curr Probl Cardiol
. 2023 Oct;
49(1 Pt C):102127.
PMID: 37802171
Heart failure with preserved ejection fraction (HFpEF) is associated with multiple cardiovascular and noncardiovascular comorbidities and risk factors which increase the risk of thrombotic complications, such as atrial fibrillation, chronic...
3.
Siniarski A, Gasecka A, Borovac J, Papakonstantinou P, Bongiovanni D, Ehrlinder H, et al.
J Card Fail
. 2023 Jan;
29(4):517-526.
PMID: 36632933
Heart failure (HF) is a clinical syndrome that is divided into 3 subtypes based on the left ventricular ejection fraction. Every subtype has specific clinical characteristics and concomitant diseases, substantially...
4.
Ehrlinder H, Orsini N, Modig K, Wallen H, Gigante B
Res Pract Thromb Haemost
. 2022 Oct;
6(7):e12823.
PMID: 36313983
Background: Risks of antithrombotic switching is not investigated in elderly atrial fibrillation patients. Objectives: To investigate the effectiveness and safety of antithrombotic treatment and switching of antithrombotic treatment in elderly...
5.
Radnahad N, Ehrlinder H, Leander K, Engdahl J, Wallen H, Gigante B
Open Heart
. 2022 Sep;
9(2).
PMID: 36171000
Objectives: To investigate the association of the heart rate-corrected QT interval (QTc) with the risk of atrial fibrillation (AF) and ischaemic stroke. Methods: We estimated the risk of AF and...
6.
Giustozzi M, Ehrlinder H, Bongiovanni D, Borovac J, Guerreiro R, Gasecka A, et al.
Blood Rev
. 2021 Jul;
50:100864.
PMID: 34217531
Sepsis is a complex syndrome with a high incidence, increasing by 8.7% annually over the last 20 years. Coagulopathy is a leading factor associated with mortality in patients with sepsis...
7.
Papakonstantinou P, Borovac J, Gasecka A, Bongiovanni D, Ehrlinder H, Giustozzi M, et al.
Eur J Prev Cardiol
. 2021 Feb;
29(15):2069-2071.
PMID: 33564838
No abstract available.
8.
Ehrlinder H, Orsini N, Modig K, Hofman-Bang C, Wallen H, Gigante B
Int J Cardiol Heart Vasc
. 2020 Apr;
27:100505.
PMID: 32258363
Background: Antithrombotic treatment represents a dilemma in elderly patients with atrial fibrillation since both risk of thromboembolism and bleeding are age-dependent complications. A paradigm shift occurred over the past 10 ...